

NervAlign® Nerve Cuff first sale and case in the US

20th of July 2022; Melbourne Australia: ReNerve Ltd (ReNerve) today announced that it has achieved the first sales of its NervAlign® Nerve Cuff device, as well as the first surgical use of the Cuff.

“This is an important commercial milestone for the company as it begins to roll out its Nerve Cuff product in the US and other markets” said ReNerve company Chairperson Stephen Cooper.

The first surgical use case was in California. ReNerve’s NervAlign® Nerve Cuff was used in a carpal tunnel repair procedure, to protect the scarred and inflamed median nerve post repair and cleaning by the surgeon. The procedure demonstrated that the Cuff was simple to implant around the nerve, with no issues during surgery and positive feedback from the surgeon on the product and its handling properties. The patient is doing well post-surgery.

ReNerve received FDA market clearance for its NervAlign® Nerve Cuff in February and full product registration in May this year. The company has been working in the US and other countries to engage with surgeons. The company has ongoing relationships with local distributors and is continuing to expand its distributor networks as well as exploring new jurisdictions.

The NervAlign® Nerve Cuff is a clean, safe collagen nerve cuff used in the protection of injured and transected nerves. The product is designed to act as an interface and provide protection to the nerve post-surgery. During the time of nerve healing, it is then absorbed through natural body processes. The NervAlign® Nerve Cuff has been shown to cause no irritation to nerves, is very pliable and readily conforms to the shape of the nerve, making for simple implantation. The Cuff is absorbed within six months post implantation, thereby leaving no foreign material behind after the nerve has repaired.

Contacts:

| |
|--|
| ReNerve Ltd Julian Chick jchick@renerve.com.au Phone: +61 (0)417 137 291 renerve.com.au |
|--|

About ReNerve

ReNerve is a medical device company specialising in biomaterial based medical devices for repair of peripheral nerve injury and related medical conditions. ReNerve’s portfolio includes a range of cleaner, safer, tissue engineered surgical products designed to enhance nerve regeneration and provide better patient outcomes. The Company’s NervAlign® Nerve Cuff has been through extensive testing, has received FDA marketing clearance and is now being marketed in the USA and elsewhere. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation program, which has supported many of the activities required to commercialise the NervAlign® Nerve Cuff. The NervAlign® Nerve Graft is an ‘off-the-shelf’, next generation product under development for the replacement of damaged nerves.